The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cytomegalovirus


Psychiatry related information on Cytomegalovirus


High impact information on Cytomegalovirus


Chemical compound and disease context of Cytomegalovirus


Biological context of Cytomegalovirus


Anatomical context of Cytomegalovirus


Gene context of Cytomegalovirus


Analytical, diagnostic and therapeutic context of Cytomegalovirus


  1. The molecular biology of leukocyte chemoattractant receptors. Murphy, P.M. Annu. Rev. Immunol. (1994) [Pubmed]
  2. Oral ganciclovir for cytomegalovirus retinitis. Van Natta, M.L., Holbrook, J. N. Engl. J. Med. (1996) [Pubmed]
  3. Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. Stagno, S., Whitley, R.J. N. Engl. J. Med. (1985) [Pubmed]
  4. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. Musch, D.C., Martin, D.F., Gordon, J.F., Davis, M.D., Kuppermann, B.D. N. Engl. J. Med. (1997) [Pubmed]
  5. Development of cytomegalovirus (CMV) retinitis in a patient with AIDS during ganciclovir therapy of CMV colitis. O'Donnell, J.J., Jacobson, M.A., Mills, J. N. Engl. J. Med. (1987) [Pubmed]
  6. Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. Revello, M.G., Gerna, G. J. Clin. Virol. (2004) [Pubmed]
  7. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Scott, J.C., Partovi, N., Ensom, M.H. Therapeutic drug monitoring. (2004) [Pubmed]
  8. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. Martin, D.F., Kuppermann, B.D., Wolitz, R.A., Palestine, A.G., Li, H., Robinson, C.A. N. Engl. J. Med. (1999) [Pubmed]
  9. Valacyclovir to prevent cytomegalovirus disease after renal transplantation. Shapiro, M.E., Abrams, J.M. N. Engl. J. Med. (1999) [Pubmed]
  10. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. Barr, M.L., Meiser, B.M., Eisen, H.J., Roberts, R.F., Livi, U., Dall'Amico, R., Dorent, R., Rogers, J.G., Radovancević, B., Taylor, D.O., Jeevanandam, V., Marboe, C.C. N. Engl. J. Med. (1998) [Pubmed]
  11. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Wiertz, E.J., Jones, T.R., Sun, L., Bogyo, M., Geuze, H.J., Ploegh, H.L. Cell (1996) [Pubmed]
  12. Oral ganciclovir as prophylaxis against cytomegalovirus. Pulido, F., Carnevali, D., Rubio, R. N. Engl. J. Med. (1996) [Pubmed]
  13. Acyclovir to prevent cytomegalovirus infection in renal-graft recipients. Grundy, J.E., Griffiths, P.D. N. Engl. J. Med. (1989) [Pubmed]
  14. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. Schilling, P.J., Vadhan-Raj, S. N. Engl. J. Med. (1990) [Pubmed]
  15. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Beck, S., Barrell, B.G. Nature (1988) [Pubmed]
  16. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Tong, L., Qian, C., Massariol, M.J., Bonneau, P.R., Cordingley, M.G., Lagacé, L. Nature (1996) [Pubmed]
  17. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Chen, P., Tsuge, H., Almassy, R.J., Gribskov, C.L., Katoh, S., Vanderpool, D.L., Margosiak, S.A., Pinko, C., Matthews, D.A., Kan, C.C. Cell (1996) [Pubmed]
  18. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Littler, E., Stuart, A.D., Chee, M.S. Nature (1992) [Pubmed]
  19. The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Ye, Y., Meyer, H.H., Rapoport, T.A. Nature (2001) [Pubmed]
  20. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Ahn, K., Gruhler, A., Galocha, B., Jones, T.R., Wiertz, E.J., Ploegh, H.L., Peterson, P.A., Yang, Y., Früh, K. Immunity (1997) [Pubmed]
  21. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Tomasec, P., Wang, E.C., Davison, A.J., Vojtesek, B., Armstrong, M., Griffin, C., McSharry, B.P., Morris, R.J., Llewellyn-Lacey, S., Rickards, C., Nomoto, A., Sinzger, C., Wilkinson, G.W. Nat. Immunol. (2005) [Pubmed]
  22. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Halary, F., Amara, A., Lortat-Jacob, H., Messerle, M., Delaunay, T., Houlès, C., Fieschi, F., Arenzana-Seisdedos, F., Moreau, J.F., Déchanet-Merville, J. Immunity (2002) [Pubmed]
  23. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Park, B., Kim, Y., Shin, J., Lee, S., Cho, K., Früh, K., Lee, S., Ahn, K. Immunity (2004) [Pubmed]
  24. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. Price, D.A., Brenchley, J.M., Ruff, L.E., Betts, M.R., Hill, B.J., Roederer, M., Koup, R.A., Migueles, S.A., Gostick, E., Wooldridge, L., Sewell, A.K., Connors, M., Douek, D.C. J. Exp. Med. (2005) [Pubmed]
  25. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. Dunn, C., Chalupny, N.J., Sutherland, C.L., Dosch, S., Sivakumar, P.V., Johnson, D.C., Cosman, D. J. Exp. Med. (2003) [Pubmed]
  26. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. Muryoi, T., Kasturi, K.N., Kafina, M.J., Cram, D.S., Harrison, L.C., Sasaki, T., Bona, C.A. J. Exp. Med. (1992) [Pubmed]
  27. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Neote, K., DiGregorio, D., Mak, J.Y., Horuk, R., Schall, T.J. Cell (1993) [Pubmed]
  28. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Cosman, D., Müllberg, J., Sutherland, C.L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., Chalupny, N.J. Immunity (2001) [Pubmed]
  29. Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. Gao, J.L., Kuhns, D.B., Tiffany, H.L., McDermott, D., Li, X., Francke, U., Murphy, P.M. J. Exp. Med. (1993) [Pubmed]
  30. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. Lee, S.H., Zafer, A., de Repentigny, Y., Kothary, R., Tremblay, M.L., Gros, P., Duplay, P., Webb, J.R., Vidal, S.M. J. Exp. Med. (2003) [Pubmed]
  31. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. Miller, D.M., Rahill, B.M., Boss, J.M., Lairmore, M.D., Durbin, J.E., Waldman, J.W., Sedmak, D.D. J. Exp. Med. (1998) [Pubmed]
  32. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. Meyers, J.D., Reed, E.C., Shepp, D.H., Thornquist, M., Dandliker, P.S., Vicary, C.A., Flournoy, N., Kirk, L.E., Kersey, J.H., Thomas, E.D. N. Engl. J. Med. (1988) [Pubmed]
  33. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. Balfour, H.H., Chace, B.A., Stapleton, J.T., Simmons, R.L., Fryd, D.S. N. Engl. J. Med. (1989) [Pubmed]
  34. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. Merigan, T.C., Renlund, D.G., Keay, S., Bristow, M.R., Starnes, V., O'Connell, J.B., Resta, S., Dunn, D., Gamberg, P., Ratkovec, R.M. N. Engl. J. Med. (1992) [Pubmed]
  35. The occupational risk of cytomegalovirus infection among day-care providers. Murph, J.R., Baron, J.C., Brown, C.K., Ebelhack, C.L., Bale, J.F. JAMA (1991) [Pubmed]
WikiGenes - Universities